KRAS and familial pancreatic carcinoma: In pancreatic cancer, a recent report showed that Ras/Raf/MEK/ERK activation induced by KRAS mutations, which are frequently observed in pancreatic cancer, plays important roles in reducing FBXW7 expression [14].